^
Association details:
Biomarker:KRAS mutation
Cancer:Melanoma
Drug:Mekinist (trametinib) (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Excerpt:
...- CRC must be KRAS or BRAF mutation positive....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors

Excerpt:
Strikingly, we observed that some of the cell lines that exhibited resistance to the single agents but were synergistically inhibited by the combination also had an activating mutation in either KRAS (SW480, SW837, DLD1, HCT116, HCT15) or loss-of-function mutations in NF1 (LOXIMVI, HCT116, RKO, MeWo; Fig. 5A; ref. 24).
DOI:
10.1158/1535-7163.MCT-15-0136-T